Arcellx, Inc. (ACLX)
- Previous Close
49.74 - Open
50.44 - Bid 49.59 x 100
- Ask 49.92 x 100
- Day's Range
48.49 - 51.18 - 52 Week Range
30.74 - 75.10 - Volume
560,886 - Avg. Volume
463,362 - Market Cap (intraday)
2.663B - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-1.03 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
80.15
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
www.arcellx.comRecent News: ACLX
Performance Overview: ACLX
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACLX
Valuation Measures
Market Cap
2.66B
Enterprise Value
2.18B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.73
Price/Book (mrq)
5.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-38.39%
Return on Assets (ttm)
-6.71%
Return on Equity (ttm)
-12.63%
Revenue (ttm)
131.66M
Net Income Avi to Common (ttm)
-50.54M
Diluted EPS (ttm)
-1.03
Balance Sheet and Cash Flow
Total Cash (mrq)
573.92M
Total Debt/Equity (mrq)
17.59%
Levered Free Cash Flow (ttm)
-61.75M
Research Analysis: ACLX
Company Insights: ACLX
ACLX does not have Company Insights